Come up with a name for your new list and we'll add to it:
Ocularis Pharma raised a round of funding on , . Investors include
Capital Midwest Fund.
Night Vision Complaints, which range from patient dissatisfaction to complete impairment due to glare, halos, starbursts, ghosting patterns, poor contrast and poor depth perception in dim light, have …